MD4177C1 - Method for vaccination against hepatitis B of persons with immunodeficiency - Google Patents

Method for vaccination against hepatitis B of persons with immunodeficiency

Info

Publication number
MD4177C1
MD4177C1 MDA20110006A MD20110006A MD4177C1 MD 4177 C1 MD4177 C1 MD 4177C1 MD A20110006 A MDA20110006 A MD A20110006A MD 20110006 A MD20110006 A MD 20110006A MD 4177 C1 MD4177 C1 MD 4177C1
Authority
MD
Moldova
Prior art keywords
persons
vaccine
immunodeficiency
vaccination
glucopyranosyl
Prior art date
Application number
MDA20110006A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD4177B1 (en
Inventor
Константин СПЫНУ
Marina Isac
Павел КИНТЯ
Владимир ГУРЬЕВ
Игорь СПЫНУ
Stepan Svet
Original Assignee
Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова filed Critical Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова
Priority to MDA20110006A priority Critical patent/MD4177C1/en
Publication of MD4177B1 publication Critical patent/MD4177B1/en
Publication of MD4177C1 publication Critical patent/MD4177C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to medicine and can be used in the prevention of viral hepatitis B to increase the effectiveness of vaccination.The method for vaccination consists in that simultaneously with hepatitis B vaccine is also administered an adaptogenic vegetal preparation with the active substance steroid glycoside 3-O-{[α-L-rhamnopyranosyl(1→3)]-[β-D-glucopyranosyl(1→2)]-β-D-glucopyranosyl}-[(25R)-furost-5-en,3β,22α,26-triol]-26-O-β-D-glucopyranoside (Mestim), in tablets of 50 mg, one tablet in the morning 30 minutes before a meal, within 30 days, beginning with the first day of administration of the vaccine.The result consists in intensifying the process of immunogenesis expressed in an increased titer of protective antibodies, which leads to a reduction in the risk of HBV infection to a minimum for persons with immunodeficiency and a reduction in the number of persons, non-respondent to the vaccine.
MDA20110006A 2011-01-14 2011-01-14 Method for vaccination against hepatitis B of persons with immunodeficiency MD4177C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20110006A MD4177C1 (en) 2011-01-14 2011-01-14 Method for vaccination against hepatitis B of persons with immunodeficiency

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20110006A MD4177C1 (en) 2011-01-14 2011-01-14 Method for vaccination against hepatitis B of persons with immunodeficiency

Publications (2)

Publication Number Publication Date
MD4177B1 MD4177B1 (en) 2012-07-31
MD4177C1 true MD4177C1 (en) 2013-02-28

Family

ID=46582439

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20110006A MD4177C1 (en) 2011-01-14 2011-01-14 Method for vaccination against hepatitis B of persons with immunodeficiency

Country Status (1)

Country Link
MD (1) MD4177C1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD667Z (en) * 2013-03-20 2014-03-31 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Method for treatment of infectious mononucleosis in children
MD782Z (en) * 2013-07-16 2015-01-31 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Method for vaccination against influenza

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189471A (en) * 1978-07-11 1980-02-19 Merck & Co., Inc. Immunologic glycolipid adjuvants
SU1162817A1 (en) * 1983-07-06 1985-06-23 Отдел Генетики Растений Ан Мсср Method of isolating trioside of /(25r)-furost-5-en-3beta-22alpha,26 triol/-26-0-beta-d-glucopyranoside
WO1988009336A1 (en) * 1987-05-29 1988-12-01 Cambridge Bioscience Corporation Saponin adjuvant
WO1993005789A1 (en) * 1991-09-18 1993-04-01 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
RU2127605C1 (en) * 1996-05-22 1999-03-20 Юрий Леонидович Криворутченко Method of stimulation of humoral and cellular immunity response to target antigen
MD1473G2 (en) * 1998-06-02 2001-05-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Antiherpetic remedy
WO2001097749A2 (en) * 2000-06-23 2001-12-27 Kotze, Gavin, Salomon The use of synthetic, non-hormonal 21-aminosteroids and thereof
MD1875G2 (en) * 1999-11-01 2002-09-30 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Method of treatment of the acute viral hepatitis B
MD2026G2 (en) * 2001-12-05 2003-05-31 Институт Физиологии Растений Академии Наук Республики Молдова Process for increasing the vine crop resistance to drought
US6905712B2 (en) * 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
MD3121G2 (en) * 2005-09-15 2007-03-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Method of viral hepatitis B prophylaxis
RU2311926C2 (en) * 2006-02-15 2007-12-10 Федеральное Агентство По Образованию Государственное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Государственный Университет" Antigen carrier and adjuvant
TW200808354A (en) * 2006-08-08 2008-02-16 Lotus Pharmaceutical Co Ltd Furost-5-ene-3,22,26-triol glucoside compounds for cancer prevention and treatment
US20100317637A1 (en) * 2009-06-16 2010-12-16 Industrial Technology Research Institute Anti-hepatitis c composition and method for preparing drug for inhibiting hepatitis c viruses or treating hepatitis c
JP2011001345A (en) * 2009-06-16 2011-01-06 Ind Technol Res Inst Anti-hepatitis c composition, method for preparing agent for inhibiting hepatitis c virus or treating hepatitis c, and use of limonoid compound
US20110218162A1 (en) * 1998-11-24 2011-09-08 Frincke James M 15-thia steroid compounds and compositions
UA98631C2 (en) * 2006-12-05 2012-06-11 Зентива, К.С. Method of purification of (s)-n-methy]-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189471A (en) * 1978-07-11 1980-02-19 Merck & Co., Inc. Immunologic glycolipid adjuvants
SU1162817A1 (en) * 1983-07-06 1985-06-23 Отдел Генетики Растений Ан Мсср Method of isolating trioside of /(25r)-furost-5-en-3beta-22alpha,26 triol/-26-0-beta-d-glucopyranoside
WO1988009336A1 (en) * 1987-05-29 1988-12-01 Cambridge Bioscience Corporation Saponin adjuvant
WO1993005789A1 (en) * 1991-09-18 1993-04-01 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
RU2127605C1 (en) * 1996-05-22 1999-03-20 Юрий Леонидович Криворутченко Method of stimulation of humoral and cellular immunity response to target antigen
MD1473G2 (en) * 1998-06-02 2001-05-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Antiherpetic remedy
US20110218162A1 (en) * 1998-11-24 2011-09-08 Frincke James M 15-thia steroid compounds and compositions
MD1875G2 (en) * 1999-11-01 2002-09-30 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Method of treatment of the acute viral hepatitis B
US6905712B2 (en) * 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
WO2001097749A2 (en) * 2000-06-23 2001-12-27 Kotze, Gavin, Salomon The use of synthetic, non-hormonal 21-aminosteroids and thereof
MD2026G2 (en) * 2001-12-05 2003-05-31 Институт Физиологии Растений Академии Наук Республики Молдова Process for increasing the vine crop resistance to drought
MD3121G2 (en) * 2005-09-15 2007-03-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Method of viral hepatitis B prophylaxis
RU2311926C2 (en) * 2006-02-15 2007-12-10 Федеральное Агентство По Образованию Государственное Образовательное Учреждение Высшего Профессионального Образования "Дальневосточный Государственный Университет" Antigen carrier and adjuvant
TW200808354A (en) * 2006-08-08 2008-02-16 Lotus Pharmaceutical Co Ltd Furost-5-ene-3,22,26-triol glucoside compounds for cancer prevention and treatment
UA98631C2 (en) * 2006-12-05 2012-06-11 Зентива, К.С. Method of purification of (s)-n-methy]-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride
US20100317637A1 (en) * 2009-06-16 2010-12-16 Industrial Technology Research Institute Anti-hepatitis c composition and method for preparing drug for inhibiting hepatitis c viruses or treating hepatitis c
JP2011001345A (en) * 2009-06-16 2011-01-06 Ind Technol Res Inst Anti-hepatitis c composition, method for preparing agent for inhibiting hepatitis c virus or treating hepatitis c, and use of limonoid compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Euvax-B. Instrucţiune de utilizare a vaccinului contra hepatitei virale B, CNSP, Chişinău, 2005 *
Types of adjuvants, Plant derivatives. Patent Landscape on Adjuvants, Patent Lens DataBase of Cambia of independent non-profit Institute, (regăsit în Internet la 2012.05.14 url: http://www.patentlens.net/daisy/adjuvants/Introduction.html ). *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD667Z (en) * 2013-03-20 2014-03-31 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Method for treatment of infectious mononucleosis in children
MD782Z (en) * 2013-07-16 2015-01-31 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Method for vaccination against influenza

Also Published As

Publication number Publication date
MD4177B1 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
Rawat et al. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies
HRP20192189T1 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
Zhao et al. Eight-year survival of AIDS patients treated with Chinese herbal medicine
MD4177C1 (en) Method for vaccination against hepatitis B of persons with immunodeficiency
Batdelger et al. Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C
MX2013003523A (en) Low dose pharmaceutical composition comprising zanamivir.
Li et al. Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination
Kelen et al. H1N1 vaccination in pediatric renal transplant patients
Jamkhande et al. A review of approved COVID-19 vaccines
RU2013120345A (en) NEW METHODS FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS
MD3121F1 (en) Method of viral hepatitis B prophylaxis
JP5846624B2 (en) H5N1 influenza vaccine and infection protection kit
JP2009263384A (en) Internal medicine for inhibiting symptom of atopic dermatitis of type i allergic disorder
MD596Z (en) Method for treating chronic viral hepatitis C in children
AL IDRISSI et al. Chloroquineand hydroxychloroquine in covid 19: asystematic review
Fried et al. A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF ORAL SILYMARIN (MILK THISTLE) FOR CHRONIC HEPATITIS C: FINAL RESULTS OF THE SYNCH MULTICENTER STUDY: 228
Bhat et al. Therapeutic Modalities in the Management of COVID-19: A Worldwide Landscape
JP2009263385A (en) Internal medicine for controlling symptom of rhinitis of type i allergic disorder
Chaudhry et al. A Review on the Advancements in COVID-19 Treatments and Vaccines
CN101244260B (en) Combined medicament for treating chronic hepatitis B
Keeffe et al. Dose-Related Increase in Virologic Responses Using Controlled Release Nitazoxanide plus Peginterferon Alfa-2a and Ribavirin for Treatment of Chronic Hepatitis C Genotype 4
RU2480206C1 (en) Method of immunocorrection of main course of treatment of destructive forms of pulmonary tuberculosis
CN103610935B (en) Medicament for treating nausea and vomiting after radiography
MX2022006054A (en) Dosage and administration of a bacterial saccharide glycoconjugate vaccine.

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees